TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07151040: A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors

Sponsor: One-carbon Therapeutics AB · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 43 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,482,320

Rescue Site Savings

+$5,615,610

Unlock Full NCT07151040 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07151040 Rescue Dossier →